Engflag

Naftidrofuryl

Quick links to important sections

Naftidrofuryl

Naftidrofuryl_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Naftidrofuryl

Property Description
Active ingredient Naftidrofuryl (typically as the oxalate salt)
Form Capsules, Tablets, Solution for Injection
Pharmacological class Peripheral Vasodilator, Serotonin 5-HT₂ Receptor Antagonist
Common purpose To improve blood circulation and cellular energy utilization
Origin Synthetic small molecule drug

What is Naftidrofuryl and What Type of Drug is it?

Naftidrofuryl is a synthetic small molecule drug primarily classified as a peripheral vasodilator, used to enhance blood flow. The medication is known by its International Nonproprietary Name (INN) Naftidrofuryl and is typically manufactured as the oxalate salt for stability. The WHO ATC classification system recognizes Naftidrofuryl under agents used in peripheral vascular diseases.

Its pharmacological class is defined by its distinctive dual action: it functions as a peripheral vasodilator and also as a selective serotonin 5-HT₂ receptor antagonist. This antagonist activity is a key differentiator, helping to prevent the excessive tightening of blood vessels. Naftidrofuryl contributes to enhanced cellular oxidative capacity and possesses a spasmolytic effect, a mechanism recognized for its benefit in improving blood flow to the extremities.

Composition and Available Pharmaceutical Forms

The active ingredient in this medication is Naftidrofuryl, prepared with appropriate pharmaceutical excipients for delivery. Naftidrofuryl is manufactured in forms suitable for both oral administration and parenteral administration.

The most common preparations are the solid oral forms, such as capsules and tablets, which are often offered in modified-release (retard) formulations. A sterile solution for injection is also produced, allowing for rapid therapeutic support in acute situations. The versatility of offering both oral and injectable options makes Naftidrofuryl adaptable for both initial treatment phases and long-term maintenance.

What is the General Purpose of Naftidrofuryl?

The general purpose of Naftidrofuryl is to support the body by improving circulation and enhancing the performance of affected tissues. It achieves this by promoting the widening of blood vessels and, concurrently, enhancing the cells' ability to utilize oxygen and glucose effectively.

This combined vascular relaxation and metabolic support is designed to address the core issue in certain chronic circulatory disorders: tissue distress due to a lack of resources. By improving both the flow of blood and the efficiency with which cells utilize it, Naftidrofuryl serves to mitigate cellular damage and support better function in muscle and nerve tissues suffering from long-term inadequate oxygen supply.

Regulatory References

  1. Serotonin, 5-HT₂ receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular diseases

What side effects are possible with Naftidrofuryl?

Regulatory Safety Profile and Adverse Reactions

The regulatory safety profile for Naftidrofuryl is defined by officially classified adverse reactions grouped by frequency and System Organ Class (SOC). The most frequently reported adverse reactions are listed as Uncommon (occurring in fewer than 1 in 100 patients). These primarily involve Gastro-intestinal disorders, such as nausea, vomiting, diarrhoea, and epigastric pain, as well as general Skin and subcutaneous tissue disorders, including skin rash.

Less frequent but more clinically significant reactions are documented. Rare effects include documented liver damage (hepatic injury). Very Rare effects involving the Renal and urinary disorders SOC include the potential for calcium oxalate kidney stones (nephrolithiasis), a risk related to the drug’s oxalate salt component. Serious effects, such as convulsions and depression of cardiac conduction, have been reported in the context of overdose.

Safety Restrictions and Contraindications

The medicine is formally contraindicated in patients with known hypersensitivity to the substance or in those with a history of hyperoxaluria or recurrent calcium-containing kidney stones. Use is not advisable during pregnancy and should not be used by breastfeeding women due to the absence of specific clinical data. Additionally, a safety note exists regarding administration context, linking the risk of local oesophagitis (frequency not known) to taking the capsules without sufficient liquid before going to bed.

Overdose and Emergency Response

Naftidrofuryl Overdose and When to Seek Help

This information describes the documented risks and required emergency actions associated with Naftidrofuryl overdosage, based strictly on official government regulatory documents.

Overdose of Naftidrofuryl has been officially associated with serious effects on the central nervous system and cardiovascular system. The main documented manifestations of an overdose are depression of cardiac conduction and convulsions.

Documented Overdose Manifestations

System Manifestation
Cardiovascular Depression of cardiac conduction
Central Nervous System Convulsions

Emergency Actions and Required Medical Management

Due to the severity of the documented risks, immediate medical attention is required for any suspected Naftidrofuryl overdose. Emergency management procedures detailed in regulatory documents include initial steps to reduce drug absorption, such as emptying the stomach by gastric lavage and emesis, with the potential use of activated charcoal.

Crucial supportive management focuses on continuous monitoring. Cardiovascular function and respiration must be closely monitored. In severe cases of toxicity, specialized interventions may be necessary. For managing profound cardiac conduction issues, treatment may involve considering electrical pacemaking or the use of isoprenaline. If convulsions occur, they are to be managed by the administration of diazepam. These steps underscore the potential life-threatening nature of Naftidrofuryl overdose.

Therapeutic Uses of Naftidrofuryl

What Naftidrofuryl Treats: Main Uses and Benefits

Naftidrofuryl is commonly used across domains where additional symptomatic support is needed to address circulatory disorders, providing relief for symptoms related to physical discomfort in the limbs. The core use is for the symptomatic management of Intermittent Claudication (IC), the painful cramping in the legs that occurs during walking due to Peripheral Arterial Disease (PAD). The medication is commonly used to help with the pain that limits walking distance, which supports patients during difficult episodes by easing distress related to mobility.

The medication is relevant for easing symptoms such as cramps in the calf and leg muscles during exercise or at night, as well as symptoms associated with painful, numb, or cold extremities. Applied in scenarios where additional management of discomfort is required, Naftidrofuryl is also considered relevant for easing more severe symptoms, including ischemic rest pain and the supportive care of trophic disorders such as chronic leg ulcers.

Quick Fact: Relief for Walking Pain
The therapy helps address symptom clusters that interfere with daily comfort, and may assist with maintaining functional stability when symptoms are more noticeable.

“The support provided assists with maintaining functional stability when symptoms of poor circulation become more noticeable.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Naftidrofuryl?

The official eligibility profile for Naftidrofuryl is strictly defined by government regulatory documents, which establish who is permitted to use the medicine and who is formally excluded.

Eligibility Scope

Classification Population/Condition Regulatory Status
Approved Population Adults with symptomatic peripheral circulatory disorders Allowed
Absolute Contraindication History of calcium oxalate kidney stones or hyperoxaluria MUST NOT USE
Age Restriction Children and adolescents under 18 years Contraindicated
Physiological Restriction Pregnancy or Breastfeeding Not Recommended

Eligibility-Context Constraints

Condition/Limitation Required Precautionary Status
Severe hepatic impairment Use with Caution and monitoring
Cardiac conduction disorders Use with Caution and monitoring

Connection to the overall eligibility profile

The regulatory documentation primarily restricts use based on two major factors: age (contraindicated in those under 18) and the metabolic risk of oxalate accumulation (contraindicated with a history of kidney stones). While allowed for most adults, caution is officially mandated for patients with pre-existing severe heart rhythm or liver conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Naftidrofuryl is defined by specific warnings against combining it with certain medicinal products and mandatory co-administration requirements with non-medicinal products.

Interaction Scope Details
Medicinal Products with Documented Interactions Monoamine Oxidase Inhibitors (MAOIs).
Mechanistic Basis of Interactions The primary interaction risk suggests a pharmacodynamic effect on vascular tone.
Timing-Based Interaction Rules Oral capsules must be swallowed during meals with a sufficient amount of water.
Interaction-Related Restrictions Co-administration with MAOIs is restricted and should be avoided.
Interaction Classifications (High-Level) Details
Interaction Severity Classification Highly Restricted Combination (MAOIs) and Mandatory Administration Condition (Food/Water).
Interaction-Context Constraints The required use with food and sufficient water is a mandatory constraint defined in regulatory documents to prevent oesophagitis and the promotion of calcium oxalate stones.

Official Interaction Statements:

  • The co-administration of Naftidrofuryl with Monoamine Oxidase Inhibitors (MAOIs) should be formally avoided due to the officially documented risk of inducing a hypertensive crisis.
  • A mandatory administration condition requires the oral capsules to be taken with both meals and a minimum of one full glass of water. This procedural constraint is in place to mitigate the documented risk of local oesophageal irritation and the formation of calcium oxalate stones.

Connection to the Overall Interaction Profile:

Regulatory documents establish a restrictive interaction structure based on a severe warning against combining it with MAOIs. This is complemented by mandatory requirements for co-administering the drug with specific products (food and water) to manage potential adverse physical and metabolic outcomes, defining the total documented interaction landscape.

Mechanism of Action

How Naftidrofuryl Works: Pharmacodynamics

Naftidrofuryl exhibits a dual mechanism of action centered on vascular modulation and cellular bioenergetics. The drug functions as a competitive antagonist primarily at the 5-hydroxytryptamine 2A ( 5-HT2 A) receptor found on vascular smooth muscle cells. This action interrupts serotonin-mediated signaling, thereby causing vascular smooth muscle relaxation and facilitating an increase in local blood flow within the microcirculation.

Concurrently, Naftidrofuryl influences intracellular processes by modulating enzymes within the mitochondrial electron transport chain, specifically impacting the rate of oxidative phosphorylation. This modulates the cell's ATP production and contributes to maintaining cellular homeostasis during periods of hypoxia (low oxygen), while also adjusting the metabolic rate of anaerobic byproducts, such as lactic acid.

The combined physiological response results from the synergy between these two mechanistic domains: the vascular action facilitates increased oxygen delivery to tissues, and the metabolic action adjusts the cell's capacity for oxygen consumption. This dual approach supports the maintenance of cellular functional stability and modulates the physiological response to conditions of reduced blood flow.

Dosage and Administration Information

How to Use Naftidrofuryl: Official Administration Guidelines

Naftidrofuryl (naftidrofuryl oxalate) is used according to specific prescribing instructions. Adherence to these guidelines is necessary for correct use.

Dosing and Administration

Administration Route Dosage Form Standard Adult Dosing (Typical) Frequency
Oral Capsule or Tablet 100 mg to 200 mg per dose Three times a day (t.i.d.)
Intravenous (IV) Solution for Infusion Dose is determined by severity of condition Administered as a slow infusion

Procedural Instructions

  • Oral Intake: Capsules and tablets must be swallowed whole with a glass of water. They should not be chewed, crushed, or divided. It is generally recommended to take the oral formulation with meals to minimize potential gastrointestinal discomfort.
  • IV Preparation: The solution for injection/infusion must be diluted in an appropriate intravenous fluid (such as normal saline) before use. It is administered via a slow intravenous infusion by a healthcare professional.

Special Population and Scheduling

  • Elderly Patients: Official labeling typically indicates that no specific dosage adjustment is required for elderly patients, though caution and monitoring are advised.
  • Impaired Organ Function: Patients with severe hepatic or renal impairment may require close monitoring and potential dose reduction or cessation, as determined by a physician, based on the drug's metabolism and excretion profile.
  • Missed Dose: If a dose is missed, the patient should not take a double dose to compensate. The next dose should be taken at the regularly scheduled time.

These instructions define the standardized approach to the physical intake and preparation of the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Naftidrofuryl

Evidence for Use in Intermittent Claudication

Research on Naftidrofuryl for Intermittent Claudication (IC) involves a significant number of studies, including Randomized Controlled Trials (RCTs) and Meta-analyses. IC is a condition where research explores outcomes related to physical discomfort during activity. These trials, which included adults with chronic, stable IC, focused on measuring outcomes reflecting functional activity, specifically the Pain-Free Walking Distance and the Maximum Walking Distance. Studies also examined patient-reported outcomes describing perceived discomfort, such as health-related quality of life.

Studies reported measurements showing changes in these walking distances over the study period. The findings describe patterns observed in the studies and contribute to the broader evidence landscape for this condition. However, the evidence is mainly based on intermediate-term follow-up durations—often about six months of observation. This means that long-term effects are not fully established or tracked over many years.

Evidence for Use in Severe Peripheral Vascular Disorders

Research has also explored settings involving severe peripheral circulatory issues, such as ischemic rest pain and trophic disorders (like chronic ulcers). The evidence base includes controlled trials involving patients with severe stages of Peripheral Arterial Occlusive Disease (PAOD). Researchers examined outcomes related to physical discomfort, tracking changes in pain severity, and monitored the characteristics of tissue lesions. The findings in systematic reviews were generally limited and characterized by heterogeneity across the individual studies. Follow-up durations were often short-term, which restricts the insight provided into long-term changes for these chronic conditions.

Long-Term Studies and Follow-Up

The primary studies on intermittent claudication typically set the observation period to about six months. Research provides insight into short-term changes, but long-term effects are not fully established. There is limited information available for outcomes that track patients for many years to see how measured changes persist. The research explored the durability of the measured walking distance changes in study populations over many years.

Evidence in Comorbidity-Defined Populations

Research has explored the inclusion of patient groups with common co-existing conditions, which are known as comorbidities. For example, some research monitored patterns related to walking distance in patients who have diabetes alongside their peripheral circulatory issues. The findings describe group patterns, not personal outcomes, and comparative data for these subgroups remains limited.

What Is Still Uncertain About Naftidrofuryl Research

Research provides context but not individual predictions. The evidence quality varies across studies; the documentation related to intermittent claudication relies on a more extensive set of data, while the data for severe peripheral vascular disorders is based on trials that often had sample sizes that were modest. Data for certain patient groups remain insufficient, and long-term effects on major clinical events, such as cardiovascular complications or mortality, are not fully tracked over many years.

How should Naftidrofuryl be stored and disposed of?

How to Store and Dispose of Naftidrofuryl

Storage and disposal requirements for Naftidrofuryl are strictly defined by regulatory documents to ensure product stability and safety.

Official Storage Conditions

Naftidrofuryl capsules must be stored under specific environmental constraints:

  • Temperature: Do not store above 25^circC.
  • Protection: The medicine must be kept in its original package to ensure adequate protection from light and moisture.
  • Child Safety: The product must be stored out of the sight and reach of children.
  • Stability: Do not use the medicine after the expiry date (EXP) printed on the packaging.

Disposal Instructions

Official labeling provides strict instructions for discarding unused or expired product:

  • Prohibition: The medicine must not be thrown away via wastewater or household waste.
  • Procedure: Individuals must consult a pharmacist for the appropriate and locally compliant method for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Naftidrofuryl found in:

A-Z Index: